407 related articles for article (PubMed ID: 38288116)
101. Central role of podocytes in mediating cellular cross talk in glomerular health and disease.
Gujarati NA; Chow AK; Mallipattu SK
Am J Physiol Renal Physiol; 2024 Mar; 326(3):F313-F325. PubMed ID: 38205544
[TBL] [Abstract][Full Text] [Related]
102. Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases.
Fukuda A; Sato Y; Shibata H; Fujimoto S; Wiggins RC
Clin Exp Nephrol; 2024 Jun; 28(6):496-504. PubMed ID: 38402504
[TBL] [Abstract][Full Text] [Related]
103. Crosstalk mechanisms between glomerular endothelial cells and podocytes in renal diseases and kidney transplantation.
Li M; Armelloni S; Mattinzoli D; Ikehata M; Chatziantoniou C; Alfieri C; Molinari P; Chadjichristos CE; Malvica S; Castellano G
Kidney Res Clin Pract; 2024 Jan; 43(1):47-62. PubMed ID: 38062623
[TBL] [Abstract][Full Text] [Related]
104. The role of podocytes in lupus nephritis: Insights and implications.
Ichinose K
Clin Immunol; 2024 May; 262():110180. PubMed ID: 38462157
[TBL] [Abstract][Full Text] [Related]
105. Mechanisms and implications of podocyte autophagy in chronic kidney disease.
Njeim R; Merscher S; Fornoni A
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F877-F893. PubMed ID: 38601984
[TBL] [Abstract][Full Text] [Related]
106. Podocyte-targeted therapies - progress and future directions.
Meliambro K; He JC; Campbell KN
Nat Rev Nephrol; 2024 May; ():. PubMed ID: 38724717
[TBL] [Abstract][Full Text] [Related]
107. Transglutaminase-mediated stiffening of the glomerular basement membrane mitigates pressure-induced reductions in molecular sieving coefficient by reducing compression.
Wang D; Ferrell N
Matrix Biol; 2024 Jun; 130():47-55. PubMed ID: 38723871
[TBL] [Abstract][Full Text] [Related]
108. Oxysterol-binding protein like 7 deficiency leads to ER stress mediated apoptosis in podocytes and proteinuria.
Duara J; Torres MF; Gurumani M; Molina David J; Njeim R; Kim JJ; Mitrofanova A; Ge M; Sloan AJ; Müller-Deile J; Schiffer M; Merscher S; Fornoni A
Am J Physiol Renal Physiol; 2024 Jul; ():. PubMed ID: 38961844
[TBL] [Abstract][Full Text] [Related]
109. Glomerular Elasticity and Gene Expression Patterns Define Two Phases of Alport Nephropathy.
Yoon J; Liu Z; Alaba M; Bruggeman LA; Janmey PA; Arana CA; Ayenuyo O; Medeiros I; Nair V; Eddy S; Kretzler M; Henderson JM; Naik AS; Chang AN; Tyler Miller R
bioRxiv; 2024 Jun; ():. PubMed ID: 38948788
[TBL] [Abstract][Full Text] [Related]
110. An ex vivo culture model of kidney podocyte injury reveals mechanosensitive, synaptopodin-templating, sarcomere-like structures.
Jiang S; Alisafaei F; Huang YY; Hong Y; Peng X; Qu C; Puapatanakul P; Jain S; Miner JH; Genin GM; Suleiman HY
Sci Adv; 2022 Sep; 8(35):eabn6027. PubMed ID: 36044576
[TBL] [Abstract][Full Text] [Related]
111. Podocyte Pathogenic Bone Morphogenetic Protein-2 Pathway and Immune Cell Behaviors in Primary Membranous Nephropathy.
Cai A; Meng Y; Zhou H; Cai H; Shao X; Wang Q; Xu Y; Zhou Y; Zhou W; Chen L; Mou S
Adv Sci (Weinh); 2024 May; ():e2404151. PubMed ID: 38785168
[TBL] [Abstract][Full Text] [Related]
112. Endotrophin neutralization through targeted antibody treatment protects from renal fibrosis in a podocyte ablation model.
An YA; Xiong W; Chen S; Bu D; Rutkowski JM; Berger JP; Kusminski CM; Zhang N; An Z; Scherer PE
Mol Metab; 2023 Mar; 69():101680. PubMed ID: 36696925
[TBL] [Abstract][Full Text] [Related]
113. Preventing MMP23-mediated cleavage of podocyte RARRES1: a novel strategy to halt chronic kidney disease progression?
Medina Rangel PX; Ishibe S
Kidney Int; 2024 Jul; 106(1):16-18. PubMed ID: 38906649
[TBL] [Abstract][Full Text] [Related]
114. Brain-Derived Neurotrophic Factor-Loaded Low-Temperature-Sensitive liposomes as a drug delivery system for repairing podocyte damage.
Huang X; Li M; Espinoza MIM; Zennaro C; Bossi F; Lonati C; Oldoni S; Castellano G; Alfieri C; Messa P; Cellesi F
Int J Pharm; 2024 Jun; 660():124322. PubMed ID: 38866082
[TBL] [Abstract][Full Text] [Related]
115. The 14th International Podocyte Conference 2023: from podocyte biology to glomerular medicine.
Koehler S; Hengel FE; Dumoulin B; Damashek L; Holzman LB; Susztak K; Huber TB;
Kidney Int; 2024 May; 105(5):935-952. PubMed ID: 38447880
[TBL] [Abstract][Full Text] [Related]
116. Transcriptomic profile of human iPSC-derived podocyte-like cells exposed to a panel of xenobiotics.
Murphy C; Jennings P; Wilmes A
Toxicol In Vitro; 2024 May; 97():105804. PubMed ID: 38447685
[TBL] [Abstract][Full Text] [Related]
117. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy.
Jiang H; Shen Z; Zhuang J; Lu C; Qu Y; Xu C; Yang S; Tian X
Front Immunol; 2023; 14():1335936. PubMed ID: 38288116
[TBL] [Abstract][Full Text] [Related]
118. [The role of podocyte injury in chronic kidney disease].
Asanuma K
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(1):26-36. PubMed ID: 25765686
[TBL] [Abstract][Full Text] [Related]
119. Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.
Sever S; Schiffer M
Kidney Int; 2018 Jun; 93(6):1298-1307. PubMed ID: 29678354
[TBL] [Abstract][Full Text] [Related]
120. Podocyte injury and its consequences.
Nagata M
Kidney Int; 2016 Jun; 89(6):1221-30. PubMed ID: 27165817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
